SHSE:688505 (China)
Â
Class A
Â¥
7.30
(-2.28%)
Jan 3
Business Description
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
ISIN : CNE100004BN8
Share Class Description:
SHSE:688505: Class ACompare
Compare
Traded in other countries / regions
01349.Hong Kong688505.ChinaFDY.Germany IPO Date
2020-06-19Description
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is engaged in the research, development, manufacturing, and sale of biopharmaceutical products. Its product portfolio includes ALA (Aminolevulinic acid Hydrochloride); FuMeiDa and Libord. Geographically, it derives revenue from Mainland China.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 100 | |||||
| Equity-to-Asset | 0.83 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.08 | |||||
| Interest Coverage | 31 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 8.54 | |||||
| Beneish M-Score | -2.29 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -3.4 | |||||
| 3-Year EBITDA Growth Rate | -15.6 | |||||
| 3-Year EPS without NRI Growth Rate | -20.6 | |||||
| 3-Year Book Growth Rate | 2.6 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 9.53 | |||||
| 9-Day RSI | 17.02 | |||||
| 14-Day RSI | 24.96 | |||||
| 6-1 Month Momentum % | 31.18 | |||||
| 12-1 Month Momentum % | -7.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.88 | |||||
| Quick Ratio | 3.77 | |||||
| Cash Ratio | 2.54 | |||||
| Days Inventory | 289.33 | |||||
| Days Sales Outstanding | 262.35 | |||||
| Days Payable | 57.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.2 | |||||
| Dividend Payout Ratio | 0.95 | |||||
| 3-Year Dividend Growth Rate | -2 | |||||
| Forward Dividend Yield % | 1.2 | |||||
| 5-Year Yield-on-Cost % | 2.05 | |||||
| Shareholder Yield % | 6.13 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 91.21 | |||||
| Operating Margin % | 13.65 | |||||
| Net Margin % | 15.16 | |||||
| FCF Margin % | 2.09 | |||||
| ROE % | 4.46 | |||||
| ROA % | 3.62 | |||||
| ROIC % | 8.62 | |||||
| ROC (Joel Greenblatt) % | 17.83 | |||||
| ROCE % | 4.23 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 22.1 | |||||
| PE Ratio without NRI | 22.52 | |||||
| Shiller PE Ratio | 12.7 | |||||
| Price-to-Owner-Earnings | 58 | |||||
| PS Ratio | 3.29 | |||||
| PB Ratio | 0.95 | |||||
| Price-to-Tangible-Book | 0.99 | |||||
| Price-to-Free-Cash-Flow | 145 | |||||
| Price-to-Operating-Cash-Flow | 50.43 | |||||
| EV-to-EBIT | 46.85 | |||||
| EV-to-EBITDA | 29.25 | |||||
| EV-to-Revenue | 6.78 | |||||
| EV-to-FCF | 330.59 | |||||
| Price-to-Projected-FCF | 1.47 | |||||
| Price-to-Graham-Number | 0.85 | |||||
| Price-to-Net-Current-Asset-Value | 1.63 | |||||
| Price-to-Net-Cash | 3.09 | |||||
| Earnings Yield (Greenblatt) % | 2.13 | |||||
| FCF Yield % | 0.25 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 691.622 | ||
| EPS (TTM) (Â¥) | 0.097 | ||
| Beta | 1.2 | ||
| Volatility % | 38.31 | ||
| 14-Day RSI | 24.96 | ||
| 14-Day ATR (Â¥) | 0.229174 | ||
| 20-Day SMA (Â¥) | 8.124 | ||
| 12-1 Month Momentum % | -7.17 | ||
| 52-Week Range (Â¥) | 6.11 - 10.29 | ||
| Shares Outstanding (Mil) | 1,043 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Frequently Asked Questions
What is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(SHSE:688505)'s stock price today?
The current price of SHSE:688505 is ¥7.30. The 52 week high of SHSE:688505 is ¥10.29 and 52 week low is ¥6.11.
When is next earnings date of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(SHSE:688505)?
The next earnings date of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(SHSE:688505) is .
Does Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(SHSE:688505) pay dividends? If so, how much?
The Dividend Yield %  of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(SHSE:688505) is 1.2% (As of Today), Highest Dividend Payout Ratio of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(SHSE:688505) was 1.03. The lowest was 0.21. And the median was 0.39. The  Forward Dividend Yield % of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd(SHSE:688505) is 1.2%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers